No results for ‘’
Vivimed Labs Ltd
₹6.26
(3.84%)
Sat, 30 May 2026, 05:38 am
Health Technology
Pharmaceuticals: Major
24.5KVivimed Labs Ratios
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 17.42 | 11.79 | 5.30 | 2.03 | 4.48 | 6.27 | 10.33 | 5.38 | 4.32 | 8.27 | 8.30 | 4.15 | 7.62 | 3.51 | 0 | 0 | 0 | 0 | 0 | 0 |
| Price to book ratio | 3.37 | 1.79 | 1 | 0.38 | 0.98 | 1.36 | 1.65 | 1.01 | 0.58 | 1.20 | 1.29 | 1.17 | 0.65 | 0.20 | 0.07 | 0.30 | 0.33 | 1.40 | 0 | 0 |
| Price to sales ratio | 2.13 | 1.20 | 0.48 | 0.14 | 0.40 | 0.74 | 0.98 | 0.41 | 0.21 | 0.43 | 0.52 | 0.61 | 0.50 | 0.15 | 0.06 | 0.15 | 0.50 | 0.30 | 0.27 | 0 |
| Price to cash flow ratio | 0 | 0 | 0 | 0 | 2.52 | 29.47 | 38.83 | 1560 | 0 | 7.12 | 6.08 | 7.96 | 0 | 0.57 | 2.92 | 0.26 | 0 | 0 | 0 | 0 |
| Enterprise value | 1.71B | 2.12B | 1.86B | 3.23B | 3.69B | 6.03B | 13.43B | 11.55B | 12.27B | 16.4B | 16.2B | 18.44B | 16.56B | 10.61B | 9.52B | 4.51B | 4.72B | 4.33B | 4.17B | 0 |
| Enterprise value to EBITDA ratio | 11.38 | 7.85 | 6.29 | 6.91 | 5.80 | 6.91 | 10.31 | 6.39 | 6.67 | 7.41 | 7.27 | 4.57 | 8.48 | 6.20 | 53.36 | 7.33 | 0 | 0 | 0 | 0 |
| Debt to equity ratio | 0.31 | 0.82 | 1.38 | 2.93 | 1.62 | 1.56 | 1.26 | 1.31 | 1.63 | 1.80 | 1.53 | 1.38 | 0.67 | 1.01 | 1.13 | 0.75 | 0.99 | 9.67 | 0 | 0 |
| Return on equity % | 0 | 23.22 | 20.74 | 20.65 | 25.07 | 28.59 | 18.81 | 17 | 12.42 | 12.88 | 14.63 | 32.44 | 7.99 | 5.29 | -12.27 | -11.35 | -17 | -162.76 | -267.63 | 0 |
Vivimed Labs Ltd Ratios
The Vivimed Labs Ltd Ratios page provides a complete fundamental analysis of Vivimed Labs Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Vivimed Labs Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.
Vivimed Labs Ltd (NSE: VIVIMEDLAB, BSE: 532660) is currently trading at ₹6.26, with a market capitalization of ₹548.89M. As a major player in the Health technology sector and Pharmaceuticals: major industry, Vivimed Labs Ltd remains a key stock for fundamental analysis using Vivimed Labs Ltd Ratios.
Vivimed Labs Ltd Ratios: Valuation Overview
Price to Earnings Ratio (P/E)
The Vivimed Labs Ltd P/E ratio currently stands at 0, making it one of the most tracked metrics in Vivimed Labs Ltd Ratios.
Historically, the Vivimed Labs Ltd P/E ratio has shown strong fluctuations:
- 2024: 0
- 2023: 0
- 2022: 0
- 2021: 0
- 2020: 0
The decline in Vivimed Labs Ltd P/E ratio suggests improving earnings relative to stock price.
Price to Book Ratio (P/B)
The Vivimed Labs Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 0.
Historical P/B trend:
- 2024: 0
- 2023: 0
- 2022: 1.40
- 2021: 0.33
Vivimed Labs Ltd shows reasonable valuation compared to its asset base.
Price to Sales Ratio (P/S)
The Vivimed Labs Ltd P/S ratio currently stands at 0, an important part of Vivimed Labs Ltd Ratios for revenue valuation.
Historical P/S ratio:
- 2024: 0
- 2023: 0.27
- 2022: 0.30
- 2021: 0.50
A stable or declining Vivimed Labs Ltd P/S ratio indicates cautious market sentiment.
Vivimed Labs Ltd Price to Cash Flow Ratio (P/CF)
The Vivimed Labs Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 0.
Historical Vivimed Labs Ltd Price to Cash Flow Ratio:
- 2024: 0
- 2023: 0
- 2022: 0
- 2021: 0
- 2020: 0.26
The declining Vivimed Labs Ltd Price to Cash Flow Ratio suggests improving cash flow strength.
Vivimed Labs Ltd Enterprise Value Ratios
Enterprise Value (EV)
The Vivimed Labs Ltd EV currently stands at ₹0, representing the total company valuation including debt.
Historical EV trend:
- 2024: 0
- 2023: 4.17B
- 2022: 4.33B
- 2021: 4.72B
Vivimed Labs Ltd enterprise value consolidation suggests stable valuation.
EV/EBITDA Ratio
The Vivimed Labs Ltd EV/EBITDA ratio is currently 0, a key metric in Vivimed Labs Ltd Ratios to assess valuation relative to earnings.
Historical EV/EBITDA:
- 2024: 0
- 2023: 0
- 2022: 0
- 2021: 0
Stable Vivimed Labs Ltd EV/EBITDA indicates balanced valuation.
Vivimed Labs Ltd Financial Strength Ratios
Debt to Equity Ratio (D/E)
The Vivimed Labs Ltd D/E ratio is currently 0, reflecting leverage and financial stability.
Historical D/E:
- 2024: 0
- 2023: 0
- 2022: 9.67
- 2021: 0.99
Vivimed Labs Ltd maintains a strong balance sheet with low debt levels.
Return on Equity (ROE %)
The Vivimed Labs Ltd ROE currently stands at 0%, showing profitability and capital efficiency.
Historical ROE:
- 2024: 0
- 2023: -267.63
- 2022: -162.76
- 2021: -17
Declining ROE indicates pressure on profitability.
Vivimed Labs Ltd Ratios Analysis Summary
The Vivimed Labs Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Vivimed Labs Ltd stock is undervalued, fairly valued, or overvalued.
Tracking Vivimed Labs Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.